Home / Resource Library / Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma – final results of the AGMT NHL15B study

Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma – final results of the AGMT NHL15B study

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma – final results of the AGMT NHL15B study